Download Hepatitis C Treatment Improvement

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Transtheoretical model wikipedia , lookup

Adherence (medicine) wikipedia , lookup

Transcript
PE 8: Deliverable A (Option One)
PE 8: Expanding Access to Services – Hepatitis C Treatment Improvement (Option One)
Quarter 1 Template
Due: April 28th, 2017
Please complete the following sections describing your project plan for expanding access to services for
patients with Hepatitis C (HCV). Each section is worth 0.50 point.
1. Basic Information:
PIP Participant name:
(if participant has more than one site)
Site(s) chosen for expansion:
# SFHP members assigned to above site(s):
2. Project Proposal:
Was the above site offering HCV treatment or
referral services prior to 1/1/17?
How many patients with HCV does the above
site(s) have?
3. Implementation Plan

Please describe your efforts on activities 1- 2- 3 listed below in italics; these activities are
required as they are best practices.

Optional: add additional sub-tasks related to the operationalization of this plan at your
organization. These activities may include stakeholder engagement, resource acquisition,
process improvements, and/or staff training.
Activity
1. Identify staff roles with respect to HCV treatment
Staff Responsible
Due Date
2. Develop HCV treatment workflows
3. Create HCV registry
 Required elements: HCV antibody status, HCV viral load
confirmation, HCV genotype, payer1, payer restrictions/
requirements (e.g. formulary)
1
If patient is covered by SFHP, we encourage your collaboration with the SFHP pharmacy team. To speak with a
pharmacy representative please call (415) 547-7818 ext 7085, and press option 3, or email [email protected]

Optional elements may include: labs, FIB-4 and/or APRI score,
cirrhosis status, particular treatment needs (e.g. unit dose,
medication storage and stability), counseling on HCV
treatment, counseling on HCV transmission including reinfection, HCV treatment medications, resistance testing,
history of prior treatment, HIV status, HBV status, DM
diagnosis, evidence of extrahepatic symptoms, other risk
factors for transmission (i.e. MSM, IDU, pregnancy potential)